Nvidia, Eli Lilly to Invest USD 1 Billion in AI Co-Innovation Lab for Drug Discovery

Nvidia, Eli Lilly to Invest USD 1 Billion in AI Co-Innovation Lab for Drug Discovery
Nvidia and Eli Lilly and Company announced on Monday the launch of what they call a first-of-its-kind AI co-innovation lab at the 44th J P Morgan Healthcare Conference, aimed at applying artificial intelligence (AI) to address long-standing challenges in pharmaceutical research and development.

  • Make Telecom Talk My Trusted Source
  • Source of Google
  • Source of Google

Investment in Talent, Infrastructure, and Compute

The two companies said they will invest up to USD 1 billion over five years in talent, infrastructure, and computing resources to support the initiative, which will combine Lilly’s expertise in drug discovery, development, and manufacturing with Nvidia’s leadership in AI, accelerated computing, and AI infrastructure.

Nvidia BioNeMo and Next-Generation AI Architectures

Based in the San Francisco Bay Area, the lab will bring together Lilly scientists and domain experts in biology and medicine with Nvidia’s AI engineers and model builders. The teams will work side by side to generate large-scale biomedical data and develop powerful AI models that can accelerate medicine development, using Nvidia BioNeMo as the core platform.

The collaboration will initially focus on building a continuous learning system that connects Lilly’s laboratory experimentation with computational AI models, enabling round-the-clock, AI-assisted research. This scientist-in-the-loop approach is expected to allow experimental data and AI models to continuously inform and improve one another.

The initiative builds on Lilly’s previously announced AI supercomputer and will leverage next-generation Nvidia architectures, including Nvidia Vera Rubin. Lilly’s AI factory — described as the most powerful in the pharmaceutical industry — will be used to train large biomedical foundation and frontier models to rapidly identify, optimize, and validate new molecules with exceptional speed and accuracy. “It will also support new and advanced applications in manufacturing, medical imaging, and scientific AI agents,” the joint statement added.